Drugbank Logo

Showing drug card for Foscarnet (DB00529)

Legend: drug field target field enzyme field

for drugs
Version 2.5
Creation Date 2005-06-13 13:24:05
Update Date 2009-06-23 18:08:22
Primary Accession Number DB00529
Secondary Accession Number
  • APRD00669
Name Foscarnet
Drug Type
  • Approved
  • Small Molecule
Description An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV. [PubChem]
Synonyms
  1. Carboxyphosphonic acid
  2. Dihydroxyphosphinecarboxylic acid oxide
  3. Forscarnet sodium
  4. Foscarnet sodium
  5. PFA
  6. Phgosphonocarboxylic acid
  7. Phosphonoformate
  8. Phosphonoformic acid
Brand Names
  1. Foscarmet
  2. Foscavir
  3. Triapten
Brand Mixtures Not Available
Chemical IUPAC Name phosphonoformic acid
Chemical Formula CH3O5P
Chemical Structure Structure
CAS Registry Number 63585-09-1
InChI Identifier InChI=1/CH3O5P/c2-1(3)7(4,5)6/h(H,2,3)(H2,4,5,6)/f/h2,4-5H
InChI Key ZJAOAACCNHFJAH-SRTMWZJWCQ
KEGG Drug D00579 Link Image
KEGG Compound Not Available
PubChem Compound 3415 Link Image
PubChem Substance 595937 Link Image
ChEBI ID Not Available
PharmGKB ID PA449706 Link Image
HET ID Not Available
GenBank ID Not Available
Drug ID Number [DIN] Not Available
RxList Link http://www.rxlist.com/cgi/generic2/foscarnet.htm Link Image
PDRhealth Link Not Available
Wikipedia Link http://en.wikipedia.org/wiki/Foscarnet Link Image
FDA Label
Material Safety Data Sheet (MSDS)
Synthesis Reference Noren, Jan O.; et al., J.Med.Chem. 26(2) 264-270(1983)
Average Molecular Weight 126.0053
Monoisotopic Molecular Weight 125.9718
State Solid
Melting Point 88.06 oC
Experimental Water Solubility Complete Source: PhysProp
Predicted Water Solubility 1.68e+01 mg/mL Calculated using ALOGPS
Experimental LogP/Hydrophobicity -2.1 Source: PhysProp
Predicted LogP -1.63 Calculated using ALOGPS
Experimental LogS Not Available
Predicted LogS -0.88 Calculated using ALOGPS
Experimental Caco2 Permeability Not Available
pKa/Isoelectric Point Not Available
Mass Spectrum Not Available
MOL File Show Link Image | Download Link Image
SDF File Show Link Image | Download Link Image
PDB File Show Link Image | Download Link Image
2D Structure
3D Structure
Experimental PDB ID Not Available
Isomeric SMILES OC(=O)P(O)(O)=O
Canonical SMILES OC(=O)P(O)(O)=O
Drug Category
  • Antiviral Agents
  • Reverse Transcriptase Inhibitors
ATC Codes
AHFS Codes Not Available
Indication For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
Pharmacology Foscarnet is an organic analogue of inorganic pyrophosphate that inhibits replication of herpes viruses in vitro including cytomegalovirus (CMV) and herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). Foscarnet does not require activation (phosphorylation) by thymidine kinase or other kinases and therefore is active in vitro against HSV TK deficient mutants and CMV UL97 mutants. Thus, HSV strains resistant to acyclovir or CMV strains resistant to ganciclovir may be sensitive to foscarnet. However, acyclovir or ganciclovir resistant mutants with alterations in the viral DNA polymerase may be resistant to foscarnet and may not respond to therapy with foscarnet. The combination of foscarnet and ganciclovir has been shown to have enhanced activity in vitro.
Mechanism of Action Foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases.
Absorption Poorly absorbed after oral administration (bioavailability from 12 to 22%).
Toxicity Oral, rat LD50: >2,000 mg/kg. Signs of overdose include renal impairment.
Protein Binding 14-17%
Biotransformation Not metabolized.
Half Life 3.3-6.8 hours
Dosage Forms
Form Route
Injection, solution Intravenous drip
Patient Information Show Link Image
Contraindications Show Link Image
Interactions Show Link Image
Drug Interactions Not Available
Food Interactions Not Available
Pathways Not Available
General References
  1. Drugs.com Link Image
  2. Wikipedia Link Image
  3. RxList Link Image
Organisms Affected
  • Human Herpes Virus
Targets
  1. DNA polymerase
  2. DNA polymerase
Drug Target 1 [top]
Target 1 ID 338
Target 1 Name DNA polymerase
Target 1 Synonyms
  1. EC 2.7.7.7
Target 1 Gene Name UL30
Target 1 Protein Sequence >DNA polymerase 
MFSGGGGPLSPGGKSAARAASGFFAPAGPRGASRGPPPCLRQNFYNPYLAPVGTQQKPTG
PTQRHTYYSECDEFRFIAPRVLDEDAPPEKRAGVHDGHLKRAPKVYCGGDERDVLRVGSG
GFWPRRSRLWGGVDHAPAGFNPTVTVFHVYDILENVEHAYGMRAAQFHARFMDAITPTGT
VITLLGLTPEGHRVAVHVYGTRQYFYMNKEEVDRHLQCRAPRDLCERMAAALRESPGASF
RGISADHFEAEVVERTDVYYYETRPALFYRVYVRSGRVLSYLCDNFCPAIKKYEGGVDAT
TRFILDNPGFVTFGWYRLKPGRNNTLAQPAAPMAFGTSSDVEFNCTADNLAIEGGMSDLP
AYKLMCFDIECKAGGEDELAFPVAGHPEDLVIQISCLLYDLSTTALEHVLLFSLGSCDLP
ESHLNELAARGLPTPVVLEFDSEFEMLLAFMTLVKQYGPEFVTGYNIINFDWPFLLAKLT
DIYKVPLDGYGRMNGRGVFRVWDIGQSHFQKRSKIKVNGMVNIDMYGIITDKIKLSSYKL
NAVAEAVLKDKKKDLSYRDIPAYYAAGPAQRGVIGEYCIQDSLLVGQLFFKFLPHLELSA
VARLAGINITRTIYDGQQIRVFTCLLRLADQKGFILPDTQGRFRGAGGEAPKRPAAARED
EERPEEEGEDEDEREEGGGEREPEGARETAGRHVGYQGARVLDPTSGFHVNPVVVFDFAS
LYPSIIQAHNLCFSTLSLRADAVAHLEAGKDYLEIEVGGRRLFFVKAHVRESLLSILLRD
WLAMRKQIRSRIPQSSPEEAVLLDKQQAAIKVVCNSVYGFTGVQHGLLPCLHVAATVTTI
GREMLLATREYVHARWAAFEQLLADFPEAADMRAPGPYSMRIIYGDTDSIFVLCRGLTAA
GLTAVGDKMASHISRALFLPPIKLECEKTFTKLLLIAKKKYIGVIYGGKMLIKGVDLVRK
NNCAFINRTSRALVDLLFYDDTVSGAAAALAERPAEEWLARPLPEGLQAFGAVLVDAHRR
ITDPERDIQDFVLTAELSRHPRAYTNKRLAHLTVYYKLMARRAQVPSIKDRIPYVIVAQT
REVEETVARLAALRELDAAAPGDEPAPPAALPSPAKRPRETPSPADPPGGASKPRKLLVS
ELAEDPAYAIAHGVALNTDYYFSHLLGAACVTFKALFGNNAKITESLLKRFIPEVWHPPD
DVAARLRTAGFGAVGAGATAEETRRMLHRAFDTLA
Target 1 Number of Residues 1255
Target 1 Molecular Weight 136422
Target 1 Theoretical pI 7.31
Target 1 GO Classification
Function
hydrolase activity
hydrolase activity, acting on ester bonds
nuclease activity
exonuclease activity
3'-5' exonuclease activity
catalytic activity
transferase activity
transferase activity, transferring phosphorus-containing groups
nucleotidyltransferase activity
DNA-directed DNA polymerase activity
nucleic acid binding
DNA binding
binding
nucleotide binding
Process
physiological process
metabolism
cellular metabolism
nucleobase, nucleoside, nucleotide and nucleic acid metabolism
DNA metabolism
DNA replication
Component
Not Available
Target 1 General Function Replication, recombination and repair
Target 1 Specific Function Not Available
Target 1 Pathways
Name SMPDB Link KEGG Link
DNA polymerase map03030 Link Image
Purine metabolism SMP00050 Link Image map00230 Link Image
Pyrimidine metabolism SMP00046 Link Image map00240 Link Image
Target 1 Reactions
  • deoxynucleoside triphosphate + DNAn = diphosphate + DNAn+1
Target 1 Pfam Domain Function
Target 1 Signals
  • None
Target 1 Transmembrane Regions
  • None
Target 1 Essentiality Non-Essential
Target 1 GenBank ID Protein 59530 Link Image
Target 1 UniProtKB/Swiss-Prot ID P04293 Link Image
Target 1 UniProtKB/Swiss-Prot Entry Name DPOL_HHV11 Link Image
Target 1 PDB ID Not Available
Target 1 Cellular Location
  • Nucleus
Target 1 Gene Sequence >3708 bp 
ATGTTTTCCGGTGGCGGCGGCCCGCTGTCCCCCGGAGGAAAGTCGGCGGCCAGGGCGGCG
TCCGGGTTTTTTGCGCCCGCCGGCCCTCGCGGAGCCAGCCGGGGACCCCCGCCTTGTTTG
AGGCAAAACTTTTACAACCCCTACCTCGCCCCAGTCGGGACGCAACAGAAGCCGACCGGG
CCAACCCAGCGCCATACGTACTATAGCGAATGCGATGAATTTCGATTCATCGCCCCGCGG
GTGCTGGACGAGGATGCCCCCCCGGAGAAGCGCGCCGGGGTGCACGACGGTCACCTCAAG
CGCGCCCCCAAGGTGTACTGCGGGGGGGACGAGCGCGACGTCCTCCGCGTCGGGTCGGGC
GGCTTCTGGCCGCGGCGCTCGCGCCTGTGGGGCGGCGTGGACCACGCCCCGGCGGGGTTC
AACCCCACCGTCACCGTCTTTCACGTGTACGACATCCTGGAGAACGTGGAGCACGCGTAC
GGCATGCGCGCGGCCCAGTTCCACGCGCGGTTTATGGACGCCATCACACCGACGGGGACC
GTCATCACGCTCCTGGGCCTGACTCCGGAAGGCCACCGGGTGGCCGTTCACGTTTACGGC
ACGCGGCAGTACTTTTACATGAACAAGGAGGAGGTCGACAGGCACCTACAATGCCGCGCC
CCACGAGATCTCTGCGAGCGCATGGCCGCGGCCCTGCGCGAGTCCCCGGGCGCGTCGTTC
CGCGGCATCTCCGCGGACCACTTCGAGGCGGAGGTGGTGGAGCGCACCGACGTGTACTAC
TACGAGACGCGCCCCGCTCTGTTTTACCGCGTCTACGTCCGAAGCGGGCGTGTGCTGTCG
TACCTGTGCGACAACTTCTGCCCGGCCATCAAGAAGTACGAGGGTGGGGTCGACGCCACC
ACCCGGTTCATCCTGGACAACCCCGGGTTCGTCACCTTCGGCTGGTACCGTCTCAAACCG
GGCCGGAACAACACGCTAGCCCAGCCGGCGGCCCCGATGGCCTTCGGGACATCCAGCGAC
GTCGAGTTTAACTGTACGGCGGACAACCTGGCCATCGAGGGGGGCATGAGCGACCTACCG
GCATACAAGCTCATGTGCTTCGATATCGAATGCAAGGCGGGGGGGGAGGACGAGCTGGCC
TTTCCGGTGGCCGGGCACCCGGAGGACCTGGTCATCCAGATATCCTGTCTGCTCTACGAC
CTGTCCACCACCGCCCTGGAGCACGTCCTCCTGTTTTCGCTCGGTTCCTGCGACCTCCCC
GAATCCCACCTGAACGAGCTGGCGGCCAGGGGCCTGCCCACGCCCGTGGTTCTGGAATTC
GACAGCGAATTCGAGATGCTGTTGGCCTTCATGACCCTTGTGAAACAGTACGGCCCCGAG
TTCGTGACCGGGTACAACATCATCAACTTCGACTGGCCCTTCTTGCTGGCCAAGCTGACG
GACATTTACAAGGTCCCCCTGGACGGGTACGGCCGCATGAACGGCCGGGGCGTGTTTCGC
GTGTGGGACATAGGCCAGAGCCACTTCCAGAAGCGCAGCAAGATAAAGGTGAACGGCATG
GTGAACATCGACATGTACGGGATTATAACCGACAAGATCAAGCTCTCGAGCTACAAGCTC
AACGCCGTGGCCGAAGCCGTCCTGAAGGACAAGAAGAAGGACCTGAGCTATCGCGACATC
CCCGCCTACTACGCCGCCGGGCCCGCGCAACGCGGGGTGATCGGCGAGTACTGCATACAG
GATTCCCTGCTGGTGGGCCAGCTGTTTTTTAAGTTTTTGCCCCATCTGGAGCTCTCGGCC
GTCGCGCGCTTGGCGGGTATTAACATCACCCGCACCATCTACGACGGCCAGCAGATCCGC
GTCTTTACGTGCCTGCTGCGCCTGGCCGACCAGAAGGGCTTTATTCTGCCGGACACCCAG
GGGCGATTTAGGGGCGCCGGGGGGGAGGCGCCCAAGCGTCCGGCCGCAGCCCGGGAGGAC
GAGGAGCGGCCAGAGGAGGAGGGGGAGGACGAGGACGAACGCGAGGAGGGCGGGGGCGAG
CGGGAGCCGGAGGGCGCGCGGGAGACCGCCGGCAGGCACGTGGGGTACCAGGGGGCCAGG
GTCCTTGACCCCACTTCCGGGTTTCACGTGAACCCCGTGGTGGTGTTCGACTTTGCCAGC
CTGTACCCCAGCATCATCCAGGCCCACAACCTGTGCTTCAGCACGCTCTCCCTGAGGGCC
GACGCAGTGGCGCACCTGGAGGCGGGCAAGGACTACCTGGAGATCGAGGTGGGGGGGCGA
CGGCTGTTCTTCGTCAAGGCTCACGTGCGAGAGAGCCTCCTCAGCATCCTCCTGCGGGAC
TGGCTCGCCATGCGAAAGCAGATCCGCTCGCGGATTCCCCAGAGCAGCCCCGAGGAGGCC
GTGCTCCTGGACAAGCAGCAGGCCGCCATCAAGGTCGTGTGTAACTCGGTGTACGGGTTC
ACGGGAGTGCAGCACGGACTCCTGCCGTGCCTGCACGTTGCCGCGACGGTGACGACCATC
GGCCGCGAGATGCTGCTCGCGACCCGCGAGTACGTCCACGCGCGCTGGGCGGCCTTCGAA
CAGCTCCTGGCCGATTTCCCGGAGGCGGCCGACATGCGCGCCCCCGGGCCCTATTCCATG
CGCATCATCTACGGGGACACGGACTCCATCTTTGTGCTGTGCCGCGGCCTCACGGCCGCC
GGGCTGACGGCCGTGGGCGACAAGATGGCGAGCCACATCTCGCGCGCGCTGTTTCTGCCC
CCCATCAAACTCGAGTGCGAAAAGACGTTCACCAAGCTGCTGCTGATCGCCAAGAAAAAG
TACATCGGCGTCATCTACGGGGGTAAGATGCTCATCAAGGGCGTGGATCTGGTGCGCAAA
AACAACTGCGCGTTTATCAACCGCACCTCCAGGGCCCTGGTCGACCTGCTGTTTTACGAC
GATACCGTCTCCGGAGCGGCCGCCGCGTTAGCCGAGCGCCCCGCGGAGGAGTGGCTGGCG
CGACCCCTGCCCGAGGGACTGCAGGCGTTCGGGGCCGTCCTCGTAGACGCCCATCGGCGC
ATCACCGACCCGGAGAGGGACATCCAGGACTTTGTCCTCACCGCCGAACTGAGCAGACAC
CCGCGCGCGTACACCAACAAGCGCCTGGCCCACCTGACGGTGTATTACAAGCTCATGGCC
CGCCGCGCGCAGGTCCCGTCCATCAAGGACCGGATCCCGTACGTGATCGTGGCCCAGACC
CGCGAGGTAGAGGAGACGGTCGCGCGGCTGGCCGCCCTCCGCGAGCTAGACGCCGCCGCC
CCAGGGGACGAGCCCGCCCCCCCCGCGGCCCTGCCCTCCCCGGCCAAGCGCCCCCGGGAG
ACGCCGTCGCCTGCCGACCCCCCGGGAGGCGCGTCCAAGCCCCGCAAGCTGCTGGTGTCC
GAGCTGGCCGAGGATCCCGCATACGCCATTGCCCACGGCGTCGCCCTGAACACGGACTAT
TACTTCTCCCACCTGTTGGGGGCGGCGTGCGTGACATTCAAGGCCCTGTTTGGGAATAAC
GCCAAGATCACCGAGAGTCTGTTAAAAAGGTTTATTCCCGAAGTGTGGCACCCCCCGGAC
GACGTGGCCGCGCGGCTCCGGACCGCAGGGTTCGGGGCGGTGGGTGCCGGCGCTACGGCG
GAGGAAACTCGTCGAATGTTGCATAGAGCCTTTGATACTCTAGCATGA
Target 1 GenBank Gene ID
Target 1 GeneCard ID Not Available
Target 1 GenAtlas ID Not Available
Target 1 HGNC ID Not Available
Target 1 Chromosome Location Not Available
Target 1 Locus Not Available
Target 1 SNPs SNPJam Report Link Image
Target 1 General References
  1. McGeoch DJ, Dalrymple MA, Davison AJ, Dolan A, Frame MC, McNab D, Perry LJ, Scott JE, Taylor P: The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol. 1988 Jul;69 ( Pt 7):1531-74. [PubMed Link Image]
  2. Quinn JP, McGeoch DJ: DNA sequence of the region in the genome of herpes simplex virus type 1 containing the genes for DNA polymerase and the major DNA binding protein. Nucleic Acids Res. 1985 Nov 25;13(22):8143-63. [PubMed Link Image]
Target 1 Drug References
  1. Tchesnokov EP, Gilbert C, Boivin G, Gotte M: Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet. J Virol. 2006 Feb;80(3):1440-50. [PubMed Link Image]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed Link Image]
  3. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed Link Image]
  4. Ducancelle A, Alain S, Petit F, Sanson Le Pors MJ, Mazeron MC: Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet. J Virol Methods. 2007 May;141(2):212-5. Epub 2007 Jan 2. [PubMed Link Image]
  5. Bonnafous P, Naesens L, Petrella S, Gautheret-Dejean A, Boutolleau D, Sougakoff W, Agut H: Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet. Antivir Ther. 2007;12(6):877-88. [PubMed Link Image]
Drug Target 2 [top]
Target 2 ID 379
Target 2 Name DNA polymerase
Target 2 Synonyms
  1. EC 2.7.7.7
Target 2 Gene Name UL54
Target 2 Protein Sequence >DNA polymerase 
MFFNPYLSGGVTGGAVAGGRRQRSQPGSAQGSGKRPPQKQFLQIVPRGVMFDGQTGLIKH
KTGRLPLMFYREIKHLLSHDMVWPCPWRETLVGRVVGPIRFHTYDQTDAVLFFDSPENVS
PRYRQHLVPSGNVLRFFGATEHGYSICVNVFGQRSYFYCEYSDTDRLREVIASVGELVPE
PRTPYAVSVTPATKTSIYGYGTRPVPDLQCVSISNWTMARKIGEYLLEQGFPVYEVRVDP
LTRLVIDRRITTFGWCSVNRYDWRQQGRASTCDIEVDCDVSDLVAVPDDSSWPRYRCLSF
DIECMSGEGGFPCAEKSDDIVIQISCVCYETGGNTAVDQGIPNGNDGRGCTSEGVIFGHS
GLHLFTIGTCGQVGPDVDVYEFPSEYELLLGFMLFFQRYAPAFVTGYNINSFDLKYILTR
LEYLYKVDSQRFCKLPTAQGGRFFLHSPAVGFKRQYAAAFPSASHNNPASTAATKVYIAG
SVVIDMYPVCMAKTNSPNYKLNTMAELYLRQRKDDLSYKDIPRCFVANAEGRAQVGRYCL
QDAVLVRDLFNTINFHYEAGAIARLAKIPLRRVIFDGQQIRIYTSLLDECACRDFILPNH
YSKGTTVPETNSVAVSPNAAIISTAAVPGDAGSVAAMFQMSPPLQSAPSSQDGVSPGSGS
NSSSSVGVFSVGSGSSGGVGVSNDNHGAGGTAAVSYQGATVFEPEVGYYNDPVAVFDFAS
LYPSIIMAHNLCYSTLLVPGGEYPVDPADVYSVTLENGVTHRFVRASVRVSVLSELLNKW
VSQRRAVRECMRECQDPVRRMLLDKEQMALKVTCNAFYGFTGVVNGMMPCLPIAASITRI
GRDMLERTARFIKDNFSEPCFLHNFFNQEDYVVGTREGDSEESSALPEGLETSSGGSNER
RVEARVIYGDTDSVFVRFRGLTPQALVARGPSLAHYVTACLFVEPVKLEFEKVFVSLMMI
CKKRYIGKVEGASGLSMKGVDLVRKTACEFVKGVTRDVLSLLFEDREVSEAAVRLSRLSL
DEVKKYGVPRGFWRILRRLVQARDDLYLHRVRVEDLVLSSVLSKDISLYRQSNLPHIAVI
KRLAARSEELPSVGDRVFYVLTAPGVRTAPQGSSDNGDSVTAGVVSRSDAIDGTDDDADG
GGVEESNRRGGEPAKKRARKPPSAVCNYEVAEDPSYVREHGVPIHADKYFEQVLKAVTNV
LSPVFPGGETARKDKFLHMVLPRRLHLEPAFLPYSVKAHECC
Target 2 Number of Residues 1262
Target 2 Molecular Weight 137103
Target 2 Theoretical pI 7.33
Target 2 GO Classification
Function
hydrolase activity
hydrolase activity, acting on ester bonds
nuclease activity
exonuclease activity
3'-5' exonuclease activity
catalytic activity
transferase activity
transferase activity, transferring phosphorus-containing groups
nucleotidyltransferase activity
DNA-directed DNA polymerase activity
nucleic acid binding
DNA binding
binding
nucleotide binding
Process
physiological process
metabolism
cellular metabolism
nucleobase, nucleoside, nucleotide and nucleic acid metabolism
DNA metabolism
DNA replication
Component
Not Available
Target 2 General Function Replication, recombination and repair
Target 2 Specific Function Not Available
Target 2 Pathways
Name SMPDB Link KEGG Link
DNA polymerase map03030 Link Image
Purine metabolism SMP00050 Link Image map00230 Link Image
Pyrimidine metabolism SMP00046 Link Image map00240 Link Image
Target 2 Reactions
  • deoxynucleoside triphosphate + DNAn = diphosphate + DNAn+1
Target 2 Pfam Domain Function
Target 2 Signals
  • None
Target 2 Transmembrane Regions
  • None
Target 2 Essentiality Non-Essential
Target 2 GenBank ID Protein 1780831 Link Image
Target 2 UniProtKB/Swiss-Prot ID P08546 Link Image
Target 2 UniProtKB/Swiss-Prot Entry Name DPOL_HCMVA Link Image
Target 2 PDB ID Not Available
Target 2 Cellular Location
  • Nucleus
Target 2 Gene Sequence >3729 bp 
TCAACAGCATTCGTGCGCCTTGACACTGTACGGCAGAAAAGCCGGCTCCAAGTGCAAGCG
CCGCGGCAGCACCATGTGCAAAAACTTGTCCTTGCGCGCGGTTTCGCCGCCGGGAAAGAC
GGGCGACAGCACGTTAGTTACAGCCTTGAGAACCTGCTCAAAGTACTTGTCGGCGTGAAT
GGGCACGCCGTGCTCGCGCACGTAGCTCGGATCTTCGGCTACCTCGTAGTTGCACACGGC
CGACGGTGGTTTCCGCGCCCTCTTCTTTGCCGGCTCTCCTCCTCTCCTGTTGCTCTCCTC
TACCCCGCCGCCGTCAGCGTCGTCGTCCGTGCCATCAATCGCGTCCGACCGGGAAACCAC
GCCGGCGGTTACAGAATCACCGTTGTCGGAGGAACCCTGCGGCGCCGTCCGGACACCGGG
CGCCGTCAGAACGTAAAAGACCCGATCCCCGACCGAGGGTAGCTCCTCAGAACGGGCCGC
CAATCGCTTAATGACGGCAATGTGCGGCAGGTTAGATTGACGGTACAGCGAGATGTCCTT
AGAGAGCACCGACGAAAGCACCAGGTCCTCGACACGCACACGGTGCAGGTACAGATCGTC
GCGGGCCTGCACCAAGCGGCGTAAGATACGCCAGAAACCGCGTGGCACGCCGTACTTCTT
GACTTCATCGAGTGAGAGGCGCGACAGGCGCACGGCTGCTTCCGAGACCTCGCGATCCTC
AAAGAGCAGCGAGAGGACGTCACGCGTGACGCCCTTGACGAACTCGCAGGCCGTCTTGCG
CACCAGATCCACGCCCTTCATGCTCAGACCCGAGGCGCCCTCCACTTTGCCGATGTAACG
TTTCTTGCAGATCATCATAAGAGAGACGAAGACCTTTTCAAACTCCAGCTTGACGGGCTC
CACAAAAAGACAGGCCGTCACGTAGTGCGCCAGGCTGGGCCCACGCGCCACCAGAGCCTG
CGGCGTCAGGCCACGAAAGCGGACAAACACGCTGTCCGTGTCCCCGTAGATGACCCGCGC
CTCCACCCGCCGTTCGTTCGAGCCCCCTGACGATGTTTCGAGCCCCTCCGGTAACGCGCT
GCTCTCCTCCGAATCCCCCTCCCGCGTTCCCACTACATAGTCTTCCTGATTAAAAAAATT
GTGCAAAAAACACGGCTCTGAAAAGTTGTCTTTGATGAACCGCGCCGTGCGCTCTAGCAT
GTCGCGACCGATGCGCGTGATGCTGGCGGCGATGGGCAGACACGGCATCATACCGTTGAC
CACGCCGGTAAAACCGTAGAAAGCGTTGCACGTTACTTTGAGCGCCATCTGTTCCTTGTC
GAGCAGCATACGGCGCACAGGGTCTTGACACTCGCGCATGCATTCGCGCACGGCACGCCG
CTGCGAAACCCACTTGTTGAGCAGTTCCGAGAGCACCGAGACGCGCACCGAAGCACGCAC
AAAGCGGTGGGTCACGCCGTTCTCTAGCGTGACGCTGTATACGTCGGCGGGGTCCACAGG
GTACTCGCCACCCGGCACCAGCAGGGTGGAGTAGCAGAGGTTGTGGGCCATGATGATGGA
AGGGTAGAGGCTGGCAAAGTCGAACACGGCCACGGGGTCGTTGTAGTAACCCACCTCGGG
CTCAAACACCGTGGCGCCCTGGTACGAAACCGCCGCAGTACCGCCGGCGCCGTGATTGTC
GTTGGAAACGCCGACGCCGCCACTACTGCCGGAGCCGACGCTGAAAACGCCGACGCTGCT
ACTACTGTTACTGCCGGAGCCGGGTGAAACGCCGTCCTGACTGGACGGCGCAGATTGCAA
GGGCGGCGACATCTGAAACATAGCCGCCACAGAACCCGCGTCGCCGGGCACAGCGGCGGT
AGAGATGATAGCAGCGTTAGGTGACACAGCAACGCTATTCGTTTCGGGCACCGTCGTACC
TTTGCTGTAGTGGTTGGGCAGGATAAAATCGCGGCAGGCGCACTCGTCCAGCAGCGAGGT
GTAGATACGGATCTGCTGTCCGTCAAAGATGACACGCCGCAACGGAATTTTAGCCAGCCG
CGCGATGGCCCCGGCCTCGTAGTGAAAATTAATGGTGTTGAACAGATCGCGCACCAATAC
GGCGTCCTGCAGACAGTAACGGCCTACCTGGGCGCGGCCCTCGGCATTAGCCACGAAACA
ACGCGGGATGTCCTTGTAAGACAGGTCATCCTTGCGTTGCCGCAGGTAAAGCTCGGCCAT
AGTGTTGAGCTTATAGTTGGGCGAGTTAGTCTTGGCCATGCATACAGGGTACATGTCGAT
AACCACCGAACCCGCAATATACACCTTGGTGGCGGCCGTGCTGGCCGGATTGTTGTGAGA
AGCCGAGGGAAAAGCGGCGGCGTACTGCCGCTTAAAACCCACGGCGGGGCTGTGTAAAAA
GAAACGGCCGCCCTGCGCCGTAGGCAACTTGCAGAAGCGCTGCGAGTCCACCTTATACAG
GTACTCGAGACGCGTGAGGATGTACTTCAAGTCAAAAGAGTTGATGTTGTAACCGGTCAC
AAAGGCCGGCGCGTACCGTTGAAAGAAAAGCATAAAGCCCAGCAGCAGCTCGTATTCGGA
AGGGAACTCGTAGACGTCCACGTCTGGGCCCACCTGCCCGCAGGTGCCGATCGTAAAGAG
ATGAAGACCCGAGTGCCCAAAGATCACACCCTCCGAAGTGCAGCCCCGACCATCGTTCCC
GTTTGGGATCCCCTGATCCACGGCGGTGTTTCCCCCCGTCTCGTAGCACACGCACGAGAT
CTGAATGACAATGTCATCGGACTTCTCGGCGCAGGGAAAACCACCCTCGCCGCTCATGCA
CTCGATATCGAAGGACAGGCATCGATAGCGCGGCCACGAGCTGTCGTCGGGCACAGCCAC
CAGGTCAGAGACATCGCAGTCTACCTCGATATCACAAGTCGACGCGCGACCCTGCTGCCG
CCAGTCGTAACGATTCACGGAGCACCAGCCGAACGTGGTGATCCGCCGATCGATGACCAA
ACGCGTCAGCGGATCCACACGGACCTCGTACACGGGAAAACCCTGCTCCAGCAGATACTC
GCCGATTTTTCTGGCCATGGTCCAGTTGCTGATAGACACACACTGCAAATCGGGCACGGG
TCGCGTCCCGTACCCATAGATGGAGGTCTTGGTGGCCGGCGTGACAGACACGGCGTATGG
CGTCCGCGGTTCGGGCACTAGTTCGCCCACGCTGGCAATGACCTCACGCAGCCTATCGGT
GTCGCTGTACTCACAGTAAAAGTAGCTGCGCTGCCCGAAAACGTTGACGCAGATACTGTA
GCCGTGTTCTGTGGCCCCGAAGAAACGCAACACGTTCCCCGAAGGCACCAGATGCTGACG
ATAGCGCGGCGACACGTTTTCGGGCGAGTCGAAGAAGAGCACGGCGTCCGTCTGATCGTA
GGTGTGAAAACGAATAGGTCCCACCACGCGACCCACCAGGGTCTCGCGCCAAGGACACGG
CCAAACCATGTCATGACTCAACAAATGTTTAATCTCTCGATAGAACATGAGAGGCAGCCG
TCCCGTCTTATGCTTGATCAACCCCGTCTGACCGTCGAACATGACACCTCGCGGCACGAT
CTGCAAAAACTGTTTCTGTGGCGGCCGCTTGCCCGAGCCCTGCGCGGAGCCGGGCTGCGA
ACGCTGACGCCGGCCACCCGCGACCGCACCGCCGGTCACGCCGCCGCTCAGATACGGGTT
GAAAAACAT
Target 2 GenBank Gene ID
Target 2 GeneCard ID Not Available
Target 2 GenAtlas ID Not Available
Target 2 HGNC ID Not Available
Target 2 Chromosome Location Not Available
Target 2 Locus Not Available
Target 2 SNPs SNPJam Report Link Image
Target 2 General References
  1. Davison AJ, Dolan A, Akter P, Addison C, Dargan DJ, Alcendor DJ, McGeoch DJ, Hayward GS: The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J Gen Virol. 2003 Jan;84(Pt 1):17-28. [PubMed Link Image]
  2. Chee MS, Bankier AT, Beck S, Bohni R, Brown CM, Cerny R, Horsnell T, Hutchison CA 3rd, Kouzarides T, Martignetti JA, et al.: Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol. 1990;154:125-69. [PubMed Link Image]
  3. Kouzarides T, Bankier AT, Satchwell SC, Weston K, Tomlinson P, Barrell BG: Sequence and transcription analysis of the human cytomegalovirus DNA polymerase gene. J Virol. 1987 Jan;61(1):125-33. [PubMed Link Image]
  4. Kouzarides T, Bankier AT, Satchwell SC, Weston K, Tomlinson P, Barrell BG: Large-scale rearrangement of homologous regions in the genomes of HCMV and EBV. Virology. 1987 Apr;157(2):397-413. [PubMed Link Image]
Target 2 Drug References
  1. Tchesnokov EP, Gilbert C, Boivin G, Gotte M: Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet. J Virol. 2006 Feb;80(3):1440-50. [PubMed Link Image]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed Link Image]
  3. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed Link Image]
  4. Ducancelle A, Alain S, Petit F, Sanson Le Pors MJ, Mazeron MC: Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet. J Virol Methods. 2007 May;141(2):212-5. Epub 2007 Jan 2. [PubMed Link Image]
  5. Bonnafous P, Naesens L, Petrella S, Gautheret-Dejean A, Boutolleau D, Sougakoff W, Agut H: Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet. Antivir Ther. 2007;12(6):877-88. [PubMed Link Image]

This project is supported by Genome Alberta & Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $600 million in funding from the federal government. This project is also supported in part by GenomeQuest, Inc., an enterprise genomic information company serving the life science community.